Glioblastoma, Glioblastoma Multiforme (GBM)
Conditions
Keywords
glioblastoma, anti-VEGF, PSMA, bevacizumab, VEGF, glioma, astrocytoma
Brief summary
This trial is a single arm study for patients receiving bevacizumab for IDH-wildtype glioblastoma. Patients receiving bevacizumab (an anti-VEGF therapy) will receive PSMA scans to investigate the role of PSMA expression in glioblastoma and its relationship to VEGF expression.
Interventions
DIAGNOSTIC_TESTPSMA PET/CT scan
PSMA PET scan will be used to monitor changes in PSMA expression in response to bevacizumab.
Sponsors
Royal North Shore Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* \> 18 year of age * ECOG 0-2 * Able to provide informed consent for the study * Minimum of 1 month from completion of radiotherapy with clinical or radiography evidence suggesting residual tumour * Confirmed glioblastoma IDH1/2 wildtype (WHO2021) * For bevacizumab treatment as per treating physician * Able to comply with trial requirements
Exclusion criteria
* No major organ impairment that would likely lead to unacceptable toxicities- eg significant cardiac, hepatic, renal or haematologic dysfunction (based on clinician assessment) * Any contraindication to bevacizumab, MRI gadolinium contrast or 68Ga-PSMA-617 radioisotope * Any implant, foreign body, 3T MRI incompatible device or other contraindication to MRI imaging * Does not fulfill PBS requirements for bevacizumab * Women lactating, pregnant or of child baring potential who are not willing to avoid pregnancy during the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in PSMA PET metabolic tumour volume (MTV) before and after bevacizumab administration. | Prior to first administration of bevacizumab to 6 weeks after. |
Countries
Australia
Contacts
CONTACTAlexander Yuile
Outcome results
None listed